About the program

Proton Pump Inhibitors: Depresecribing and Polypharmacy Reduction is the best discussion of the risks and benefits of those drugs that I have ever seen in any medical conference

– Alan Cassels, Author, journalist and drug policy researcher.

Date: Thursday, June 18 – 8:00pm EST

Presenter: John Gannage, MD, CCFP, FMAPS

Proton pump inhibitors (PPIs) are among the most frequently prescribed medications, yet research suggests they may be overused and lead to serious health risks.

In this presentation Dr. John Gannage examines the potential dangers of long-term PPI use, including increased risks of cardiovascular events, kidney disease, infections, and nutrient deficiencies. The program content also provides practical information on deprescribing PPIs and supporting optimal digestion through non-pharmaceutical interventions.

At the conclusion of this activity, participants will be able to:

  • Recognize the risks associated with long-term PPI use, including drug-induced nutrient depletion.
  • Analyze the underlying causes of low stomach acid and understand the functional implications of blocking its production.
  • Identify the rationale for deprescribing proton-pump inhibitors, particularly in the context of polypharmacy reduction and the management of chronic disease.
  • Evaluate non-pharmaceutical interventions for managing reflux symptoms and supporting digestive function.

This 1-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada for up to 1.25 Mainpro+ credits.

Scholarships available for students and residents currently enrolled in medical, nurse practitioner or pharmacy programs. Scholarship application

CME Planning Committee

Rose Bilotta, MD, MHSc, CCFP, FRCPC, DABPM, IFMCP
Selena Bloom, MD, MCFP, SEP
John Gannage, MD, CCFP, FMAPS

Tickets

The numbers below include tickets for this event already in your cart. Clicking "Get Tickets" will allow you to edit any existing attendee information as well as change ticket quantities.
Proton Pump Inhibitors: Deprescribing and Polypharmacy Reduction
$ 89.00
Unlimited